News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>G Sachs: CN Healthcare Sector to Be More Normalized This Yr w/ No V-shape Recovery in Sight
2025 will be a more normalized year for China's healthcare industry, with pharma firms expected to gradually adapt to the new norm, Goldman Sachs released a research report say...
Reset
Send
The window will close in 5 seconds
<Research>G Sachs: CN Healthcare Sector to Be More Normalized This Yr w/ No V-shape Recovery in Sight
Close
Recommend
33
Positive
47
Negative
18
 
SHORT SELL
 
STOCK INFO

2025 will be a more normalized year for China's healthcare industry, with pharma firms expected to gradually adapt to the new norm, Goldman Sachs released a research report saying.

However, the industry is not yet expected to quickly recover from the impact of policies like recent anti-corruption, national healthcare insurance disease diagnosis related group (DRG) reform and achieve a V-shape recovery.

Related NewsBofAS Lifts SINO BIOPHARM's TP to HKD5.9, Reiterating Buy Rating
In addition, Goldman Sachs believed that the application of AI is too early to have a significant impact on the industry in the short term, although generative AI has become a buzzword in the pharma industry.

Goldman Sachs lowered its target price for covered Chinese healthcare companies by -8% to +13%, based on recent industry development trends, including more policy support for innovative drugs, the impact of volume-based procurement on biosimilars and the demand and price trend of APIs, etc..

Currently, Goldman Sachs rated HANSOH PHARMA (03692.HK)  -0.050 (-0.180%)    Short selling $180.96M; Ratio 35.646%   , SINO BIOPHARM (01177.HK)  +0.100 (+2.062%)    Short selling $145.25M; Ratio 19.652%   and CSPC PHARMA (01093.HK)  -0.080 (-1.051%)    Short selling $260.30M; Ratio 10.582%   at Buy, with ratings at Neutral on FOSUN PHARMA (02196.HK)  0.000 (0.000%)    Short selling $6.02M; Ratio 5.406%   , LIVZON PHARMA (01513.HK)  -0.400 (-1.361%)    Short selling $2.64M; Ratio 4.492%   , 3SBIO (01530.HK)  -0.150 (-0.719%)    Short selling $104.83M; Ratio 10.766%   , UNITED LAB (03933.HK)  -0.180 (-1.155%)    Short selling $15.07M; Ratio 11.637%   , SINOPHARM (01099.HK)  +0.140 (+0.766%)    Short selling $77.75M; Ratio 47.001%   and CHINARES PHARMA (03320.HK)  +0.020 (+0.393%)    Short selling $9.71M; Ratio 18.591%   . The broker also rated HEPALINK (09989.HK)  -0.060 (-1.149%)   and SH PHARMA (02607.HK)  +0.080 (+0.703%)    Short selling $9.19M; Ratio 16.881%   at Sell.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-19 16:25.)

Related NewsSPDB Int’l Lists Top 20 Stocks in Terms of Net Southbound Capital Inflow in Past Mth (Table)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.